Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
J Am Acad Dermatol ; 90(4): 798-805, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38081390

ABSTRACT

BACKGROUND: Amid a movement toward value-based healthcare, increasing emphasis has been placed on outcomes and cost of medical services. To define and demonstrate the quality of services provided by Mohs surgeons, it is important to identify and understand the key aspects of Mohs micrographic surgery (MMS) that contribute to excellence in patient care. OBJECTIVE: The purpose of this study is to develop and identify a comprehensive list of metrics in an initial effort to define excellence in MMS. METHODS: Mohs surgeons participated in a modified Delphi process to reach a consensus on a list of metrics. Patients were administered surveys to gather patient perspectives. RESULTS: Twenty-four of the original 66 metrics met final inclusion criteria. Broad support for the initiative was obtained through physician feedback. LIMITATIONS: Limitations of this study include attrition bias across survey rounds and participation at the consensus meeting. Furthermore, the list of metrics is based on expert consensus instead of quality evidence-based outcomes. CONCLUSION: With the goal of identifying metrics that demonstrate excellence in performance of MMS, this initial effort has shown that Mohs surgeons and patients have unique perspectives and can be engaged in a data-driven approach to help define excellence in the field of MMS.


Subject(s)
Skin Neoplasms , Surgeons , Humans , Skin Neoplasms/surgery , Mohs Surgery , Consensus , Benchmarking
2.
Int J Dermatol ; 60(8): 986-990, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33742703

ABSTRACT

BACKGROUND: Limited data are available on the development of skin cancer and the associated risk factors for non-White liver transplant (LT) recipients. The aim of this study is to determine the incidence of newly diagnosed skin cancer postoperatively and to identify the risk factors for the development of skin cancer in non-White LT recipients. METHODS: We conducted an initial retrospective chart review of non-White LT patients who received a transplant at our center between January 1, 2011, and December 31, 2013. RESULTS: Of the 96 patients in the study cohort, 32% were Black, 17% were Asian, 15% were White Hispanic, and 10% were Black Hispanic. One patient had a history of nonmelanoma skin cancer before transplant. No skin cancers were diagnosed during follow-up (median, 1.3 years; range, 17 days to 8.6 years). CONCLUSION: Our center's experience is consistent with the literature and suggests that the incidence of newly diagnosed skin cancer in non-White liver transplant recipients is low. Longer follow-up may provide additional insights into the specific risk factors for the posttransplant development of skin cancer.


Subject(s)
Liver Transplantation , Skin Neoplasms , Cohort Studies , Humans , Incidence , Liver Transplantation/adverse effects , Retrospective Studies , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology
4.
J Am Acad Dermatol ; 82(4): 946-954, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31836564

ABSTRACT

BACKGROUND: Vismodegib demonstrated 60% response rates in the ERIVANCE trial. Basal cell carcinoma has various histopathologies. Their effect on response is unclear. OBJECTIVE: The purpose of this study was to determine whether basal cell carcinoma histopathology affected vismodegib response. METHODS: This phase 2b, single-center, prospective case series study compared the efficacy of vismodegib in infiltrative, nodular, and superficial basal cell carcinomas treated for 12 or 24 weeks in 27 patients. Patients had 1 target lesion and up to 3 nontarget lesions. RESULTS: Twenty-seven patients were enrolled, with 65 tumors (27 target lesions/38 nontarget lesions). At 24 weeks, most basal cell carcinomas achieved histologic clearance, with positive biopsy results in 10.5% of target lesions, 30.4% of nontarget lesions, and 21.4% overall. No statistical differences were observed between histopathologic subtypes. One hundred percent of patients experienced an adverse event, 94% grade 1 or 2. The most common adverse events were dysgeusia/loss of taste (86%), muscle spasms (82%), and alopecia (71%). Clinically progressive disease during treatment was low (1.5%). Two patients had recurrence within 1 year of treatment. LIMITATIONS: Limitations included sample size of basal cell carcinoma histopathologic subtypes, sampling punch biopsies, and short follow-up. CONCLUSIONS: Basal cell histopathologic subtype did not significantly affect response to vismodegib. Each subtype was observed to completely respond at 12 weeks of therapy, 24 weeks, or both.


Subject(s)
Anilides/administration & dosage , Antineoplastic Agents/administration & dosage , Carcinoma, Basal Cell/drug therapy , Neoplasm Recurrence, Local/epidemiology , Pyridines/administration & dosage , Skin Neoplasms/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Alopecia/chemically induced , Alopecia/epidemiology , Anilides/adverse effects , Antineoplastic Agents/adverse effects , Biopsy , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/pathology , Drug Administration Schedule , Dysgeusia/chemically induced , Dysgeusia/epidemiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Prospective Studies , Pyridines/adverse effects , Skin/pathology , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Spasm/chemically induced , Spasm/epidemiology , Treatment Outcome
5.
J Am Acad Dermatol ; 82(3): 700-708, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31756403

ABSTRACT

BACKGROUND: Opioid overprescribing is a major contributor to the opioid crisis. The lack of procedure-specific guidelines contributes to the vast differences in prescribing practices. OBJECTIVE: To create opioid-prescribing consensus guidelines for common dermatologic procedures. METHODS: We used a 4-step modified Delphi method to conduct a systematic discussion among a panel of dermatologists in the fields of general dermatology, dermatologic surgery, and cosmetics/phlebology to develop opioid prescribing guidelines for some of the most common dermatologic procedural scenarios. Guidelines were developed for opioid-naive patients undergoing routine procedures. Opioid tablets were defined as oxycodone 5-mg oral equivalents. RESULTS: Postoperative pain after most uncomplicated procedures (76%) can be adequately managed with acetaminophen and/or ibuprofen. Group consensus identified no specific dermatologic scenario that routinely requires more than 15 oxycodone 5-mg oral equivalents to manage postoperative pain. Group consensus found that 23% of the procedural scenarios routinely require 1 to 10 opioid tablets, and only 1 routinely requires 1 to 15 opioid tablets. LIMITATIONS: These recommendations are based on expert consensus in lieu of quality evidence-based outcomes research. These recommendations must be individualized to accommodate patients' comorbidities. CONCLUSIONS: Procedure-specific opioid prescribing guidelines may serve as a foundation to produce effective and responsible postoperative pain management strategies after dermatologic interventions.


Subject(s)
Analgesics, Opioid/therapeutic use , Dermatology , Drug Prescriptions/standards , Pain, Postoperative/drug therapy , Practice Patterns, Physicians' , Dermatologic Surgical Procedures , Female , Humans , Male , Practice Guidelines as Topic
6.
JAMA Otolaryngol Head Neck Surg ; 145(11): 1064-1072, 2019 Nov 01.
Article in English | MEDLINE | ID: mdl-31580395

ABSTRACT

IMPORTANCE: Melanoma is one of the most common cancers worldwide, typically diagnosed in older adults. There is an increasing incidence in the younger population (age ≤40 years) in America. In addition, approximately 1 in 5 cases of melanoma affect the head and neck. However, there are limited data on the incidence of head and neck melanoma in the pediatric, adolescent, and young adult population in North America (United States and Canada). OBJECTIVE: To assess 20-year demographic and incidence changes associated with head and neck melanoma in the pediatric, adolescent, and young adult population in North America. DESIGN, SETTING, AND PARTICIPANTS: A descriptive analysis of retrospective data on head and neck melanoma from the North American Association of Central Cancer Registries' Cancer in North America public use data set from 1995 to 2014 was conducted. The data set currently includes 93% of the United States and 64% of the Canadian populations. Eligible data were from 12 462 pediatric, adolescent, and young adult patients (aged 0-39 years) with a confirmed diagnosis of melanoma (International Classification of Diseases-Oncology 3 histologic types 8720-8790) in primary head and neck sites: skin of lip, not otherwise specified (C44.0); eyelid (C44.1); external ear (C44.2); skin of other/unspecified parts of face (C44.3); and skin of scalp and neck (C44.4). The study was conducted from January 26 to July 21, 2019. MAIN OUTCOMES AND MEASURES: Log-linear regression was used to estimate annual percentage change in age-adjusted incidence rates (AAIRs) of head and neck melanoma. RESULTS: Of the 12 462 patients with head and neck melanoma included in the study, 6810 were male (54.6%). The AAIR was 0.51 per 100 000 persons (95% CI, 0.50-0.52 per 100 000 persons). In North America, the incidence of head and neck melanoma increased by 51.1% from 1995 to 2014. The rate was higher in the United States (AAIR, 0.52; 95% CI, 0.51-0.53 per 100 000 person-years) than Canada (AAIR, 0.43; 95% CI, 0.40-0.45 per 100 000 persons). In the United States, the incidence increased 4.68% yearly from 1995 to 2000 and 1.15% yearly from 2000 to 2014. In Canada, the incidence increased 2.18% yearly from 1995 to 2014. Male sex (AAIR, 0.55; 95% CI, 0.54-0.57 per 100 000 persons), older age (AAIR, 0.79; 95% CI, 0.79-0.80 per 100 000 persons), and non-Hispanic white race/ethnicity (AAIR, 0.79; 95% CI, 0.77-0.80 per 100 000 persons) were associated with an increased incidence of head and neck melanoma. CONCLUSIONS AND RELEVANCE: The incidence of pediatric, adolescent, and young adult head and neck melanoma in North America appears to have increased by 51.1% in the past 2 decades, with males aged 15 to 39 years the main cohort associated with the increase.

7.
Transpl Int ; 32(12): 1268-1276, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31502728

ABSTRACT

Skin cancer is the most common malignancy affecting solid organ transplant recipients (SOTR), and SOTR experience increased skin cancer-associated morbidity and mortality. There are no formal multidisciplinary guidelines for skin cancer screening after transplant, and current practices are widely variable. We conducted three rounds of Delphi method surveys with a panel of 84 U.S. dermatologists and transplant physicians to establish skin cancer screening recommendations for SOTR. The transplant team should risk stratify SOTR for screening, and dermatologists should perform skin cancer screening by full-body skin examination. SOTR with a history of skin cancer should continue regular follow-up with dermatology for skin cancer surveillance. High-risk transplant patients include thoracic organ recipients, SOTR age 50 and above, and male SOTR. High-risk Caucasian patients should be screened within 2 years after transplant, all Caucasian, Asian, Hispanic, and high-risk African American patients should be screened within 5 years after transplant. No consensus was reached regarding screening for low-risk African American SOTR. We propose a standardized approach to skin cancer screening in SOTR based on multidisciplinary expert consensus. These guidelines prioritize and emphasize the need for screening for SOTR at greatest risk for skin cancer.


Subject(s)
Delphi Technique , Early Detection of Cancer/methods , Organ Transplantation/adverse effects , Skin Neoplasms/diagnosis , Consensus , Female , Guidelines as Topic , Humans , Male , Risk Assessment , Skin Neoplasms/epidemiology , Transplant Recipients , United States
9.
J Cutan Pathol ; 44(8): 713-721, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28556973

ABSTRACT

PEComas represent a family of uncommon mesenchymal tumors composed of "perivascular epithelioid cells" with a distinct immunophenotype that typically shows both myogenic and melanocytic differentiation. The PEComa family includes angiomyolipoma (AML), clear cell "sugar" tumor of the lung and extra pulmonary sites, lymphangioleiomyomatosis and clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres. Very rarely, PEComas may arise in the skin. Primary cutaneous PEComas typically display a dermal proliferation of epithelioid cells with pale, clear, or granular pink cytoplasm arranged in nests and trabecula with an intervening arborizing network of delicate capillaries. Primary cutaneous PEComas have a lower frequency of myogenic marker expression than their deep soft tissue and visceral counterparts. They also often express strong diffuse CD10, leading to potential confusion with metastatic renal cell carcinoma. Most cases behave indolently. We report 5 additional cases of this rare entity. All showed classic histologic features and expression of either HMB-45 and/or Melan-A/MART-1. Four cases were tested for myogenic markers (2 were positive & 2 were negative). Three cases were tested for CD10 (all 3 were positive). All of our cases with clinical follow-up behaved indolently. Table 1 provides a summary of findings for all 5 cases in our series.


Subject(s)
Cell Proliferation , Dermis , Neoplasm Proteins/metabolism , Perivascular Epithelioid Cell Neoplasms , Skin Neoplasms , Adult , Aged , Dermis/metabolism , Dermis/pathology , Female , Humans , Male , Middle Aged , Perivascular Epithelioid Cell Neoplasms/metabolism , Perivascular Epithelioid Cell Neoplasms/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
11.
Dermatol Surg ; 42(12): 1320-1324, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27893492

ABSTRACT

BACKGROUND: Intracutaneous lidocaine is used for anesthesia in dermatologic surgery for skin cancer excision and repair with exceedingly low incidence of reported adverse events. OBJECTIVE: To measure (1) the quantity of lidocaine typically used for facial skin cancer excision and reconstruction; and (2) the frequency and character of associated adverse events. METHODS: Survey study of dermatologic surgeons with longitudinal reporting. Reported practice during 10 business days: (1) mean volume of 1% lidocaine per skin cancer excision; (2) maximum per excision; (3) mean per reconstruction; and (4) maximum per reconstruction. RESULTS: A total of 437 of 1,175 subjects contacted (37.2%) responded. Mean per excision was 3.44 mL (SD: 2.97), and reconstruction 11.70 mL (10.14). Maximum per excision was 6.54 mL (4.23), and reconstruction was 15.85 mL (10.39). No cases of lidocaine toxicity were reported, diagnosed, or treated. Incidence of adverse events possibly anesthesia related was >0.15%, with most (0.13%) being mild cases of dizziness, drowsiness, or lightheadedness from epinephrine tachycardia. CONCLUSION: Toxicity associated with local anesthesia other than lidocaine was not studied. Volumes of lidocaine in skin cancer excision and repair are modest and within safe limits. Lidocaine toxicity is exceedingly rare to entirely absent. For comparable indications, lidocaine is safer than conscious sedation or general anesthesia.


Subject(s)
Anesthesia, Local/methods , Anesthetics, Local/administration & dosage , Head and Neck Neoplasms/surgery , Lidocaine/administration & dosage , Practice Patterns, Physicians'/statistics & numerical data , Skin Neoplasms/surgery , Anesthesia, Local/adverse effects , Anesthetics, Local/adverse effects , Cross-Sectional Studies , Epinephrine/administration & dosage , Epinephrine/adverse effects , Humans , Injections, Intradermal , Lidocaine/adverse effects , Longitudinal Studies , Mohs Surgery , Patient Safety , Plastic Surgery Procedures , United States
14.
Dermatol Ther ; 28(6): 359-62, 2015.
Article in English | MEDLINE | ID: mdl-26114264

ABSTRACT

We report an 83 year-old patient with a 13 × 7.5 cm(2) basal cell carcinoma (BCC) successfully treated with the combination of vismodegib and minimal surgery. On Day 109, a 0.9 cm papule suspicious for residual BCC was seen centrally within a large pink atrophic plaque. This lesion was excised; pathology confirmed BCC with negative surgical margins. Simultaneously, suspecting noncontiguous histologic response, we performed 21 biopsies at the periphery of the pretreatment tumor location. Seventeen (17/21, 81%) revealed lichenoid dermatitis. No tumor was seen on any. We believe the lichenoid dermatitis observed is a novel finding for two reasons. First, it may be considered a marker of a positive intratreatment response. This may help guide clinicians on the optimal treatment duration of vismodegib to maximize efficacy and mitigate side effects. Second, we think it suggests an additional mechanism of vismodegib action, possibly via local immune effects. Further investigations are warranted.


Subject(s)
Anilides/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Lichenoid Eruptions/chemically induced , Neoadjuvant Therapy , Pyridines/therapeutic use , Skin Neoplasms/drug therapy , Aged, 80 and over , Anilides/adverse effects , Antineoplastic Agents/adverse effects , Biopsy , Carcinoma, Basal Cell/immunology , Carcinoma, Basal Cell/pathology , Carcinoma, Basal Cell/surgery , Chemotherapy, Adjuvant , Humans , Lichenoid Eruptions/immunology , Lichenoid Eruptions/pathology , Male , Neoadjuvant Therapy/adverse effects , Pyridines/adverse effects , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Treatment Outcome , Tumor Burden
16.
Dermatol Surg ; 41(7): 794-802, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26066617

ABSTRACT

BACKGROUND: Postsurgical scalp wounds that extend to the calvarium present a challenge for repair, especially in the elderly patient with multiple comorbidites. When second-intention healing is selected for closure, patients often have prolonged healing times. OBJECTIVE: To assess the clinical outcomes of animal-derived collagen xenograft placement on postsurgical scalp wounds extending to the calvarium. METHODS: Eleven patients (ages, 61 through 95 years) with calvarium-exposed wounds treated solely with bovine-derived collagen xenografts were reviewed with follow-up extending 12 to 30 weeks after initial surgery. RESULTS: Increased rates of healing were found in the xenograft-treated wounds as compared with previous studies of calvarium-exposed wounds healed by second intention alone. Advantages of animal-derived collagen xenografts include immediate coverage of the wound, simple application, low cost, and avoidance of the morbidity associated with local flap, graft, and free flap repairs. CONCLUSION: In patients with postsurgical scalp defects with exposed calvarium, collagen xenograft placement may expedite second-intention healing and offer other advantages in the elderly population.


Subject(s)
Head and Neck Neoplasms/surgery , Plastic Surgery Procedures/methods , Scalp/surgery , Skin, Artificial , Skull/surgery , Wound Healing/physiology , Aged , Aged, 80 and over , Animals , Biocompatible Materials , Cattle , Collagen , Female , Heterografts , Humans , Male , Middle Aged , Mohs Surgery , Treatment Outcome
17.
J Skin Cancer ; 2014: 154340, 2014.
Article in English | MEDLINE | ID: mdl-25309755

ABSTRACT

Recent guidelines from the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) have been proposed for the assessment of "high-risk" cutaneous squamous cell carcinomas (cSCCs). Though different in perspective, both guidelines share the common goals of trying to identify "high-risk" cSCCs and improving patient outcomes. Thus, in theory, both definitions should identify a similar proportion of "high-risk" tumors. We sought to evaluate the AJCC and NCCN definitions of "high-risk" cSCCs and to assess their concordance. Methods. A retrospective review of head and neck cSCCs seen by an academic dermatology department from July 2010 to November 2011 was performed. Results. By AJCC criteria, most tumors (n = 211,82.1%) were of Stage 1; 46 tumors (13.9%) were of Stage 2. Almost all were of Stage 2 due to size alone (≥2 cm); one tumor was "upstaged" due to "high-risk features." Using the NCCN taxonomy, 231 (87%) of tumors were "high-risk." Discussion. This analysis demonstrates discordance between AJCC and NCCN definitions of "high-risk" cSCC. Few cSCCs are of Stage 2 by AJCC criteria, while most are "high-risk" by the NCCN guidelines. While the current guidelines represent significant progress, further studies are needed to generate a unified definition of "high-risk" cSCC to optimize management.

19.
JAMA Dermatol ; 150(2): 169-76, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24285085

ABSTRACT

IMPORTANCE Little is known about patients' experiences of advanced basal cell carcinoma (aBCC) and basal cell carcinoma nevus syndrome (BCCNS), a rare genetic disorder that greatly increases the number of BCCs. OBJECTIVE To develop a questionnaire to measure patient-reported outcomes (PROs) in these populations. DESIGN, SETTING, AND PARTICIPANTS Concept elicitation interviews were conducted with patients with aBCC and BCCNS from 5 US clinical sites and the BCCNS Life Support Network and 4 physicians. The PRO questionnaires were drafted based on results from a literature review and findings from these interviews. Questionnaires were finalized after cognitive debriefing interviews were conducted with patients. Concept elicitation interviews were conducted with 30 patients (14 with aBCC, 16 with BCCNS) and 4 physicians (2 dermatologists, 1 Mohs surgeon, and 1 oncologist) in the United States. A subset of 10 of these patients (5 with aBCC, 5 with BCCNS) took part in cognitive debriefing interviews. MAIN OUTCOMES AND MEASURES Development of 2 questionnaires to allow clinicians to assess the emotional, social, and physical impacts of the disease on patients with aBCC and BCCNS. RESULTS Most concept elicitation interview patients were male (63%) and white (93%); their mean age was 57 years. There were impacts on emotional, social, and physical functioning in both conditions. Patients were unable to do many activities and avoided other activities. Seventy-nine percent of patients with aBCC and all patients with BCCNS reported scarring. Physician interviews revealed similar findings. During cognitive debriefing interviews, the questionnaires were found to be relevant, clear, and comprehensive. CONCLUSIONS AND RELEVANCE Advanced BCC and BCCNS affect patients in unique and substantial ways. These PRO questionnaires were developed with patient and clinician input and measure the key areas that have an impact on patients with these conditions.


Subject(s)
Basal Cell Nevus Syndrome/pathology , Carcinoma, Basal Cell/pathology , Quality of Life , Skin Neoplasms/pathology , Surveys and Questionnaires , Adult , Aged , Basal Cell Nevus Syndrome/psychology , Carcinoma, Basal Cell/psychology , Female , Humans , Male , Middle Aged , Skin Neoplasms/psychology
20.
Chemother Res Pract ; 2013: 726925, 2013.
Article in English | MEDLINE | ID: mdl-23762555

ABSTRACT

A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median age was 52.2 years (26.8-61.1 years). One patient started treatment with lung lesions only (after resection of melanoma brain disease) and experienced partial response. Seven patients had brain metastases at treatment initiation. Median overall survival (mOS) for entire cohort (n = 8) was 8.7 months (2.1 to 19.0 months). All patients with brain metastases at first dose (n = 7) showed progressive disease; mOS was 6.7 months (range 2.1-18.2 months) for this group. Patients received radiosurgery and whole brain radiation before and after HD IL-2 therapy. One patient had symptoms suggestive of neurotoxicity. A history of alcohol abuse was revealed during admission. The patient's symptoms improved with initiation of an alcohol withdrawal protocol. In this analysis, patients with melanoma brain metastases received HD IL-2 without treatment-related mortality. We think that HD IL-2 should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy.

SELECTION OF CITATIONS
SEARCH DETAIL
...